Department of Neurosurgery, University of Florida, Gainesville, FL 32610, USA.
J Neurointerv Surg. 2012 Sep;4(5):375-8. doi: 10.1136/neurintsurg-2011-010106. Epub 2011 Sep 13.
Hydrosoft coils were developed to serve as finishing coils to prevent aneurysmal recurrence at the neck. Initial animal studies were encouraging since some studies showed endothelial healing across the neck without recurrence over time. However, theoretical concerns exist regarding the potential threat to parent vessels as the Hydrosoft coils at the neck expand, as well as whether such coils can be adequately supple to safely serve as a true finishing coil. A retrospective review of the initial clinical experience utilizing Hydrosoft coils from three high-volume centers was performed.
Each center was asked to report angiographic (aneurysmal location, aneurysmal maximal size, neck size, incidence of intraprocedural parent vessel thrombosis, coil herniation, aneurysmal rupture as well as Raymond scale and percent occlusion after coiling) and clinical (rupture status, Hunt and Hess grade, incidence of stroke, hemorrhage, vasospasm and hydrocephalus) data on consecutive patients who underwent placement of Hydrosoft coils.
A total of 141 patients were enrolled. Embolization achieved a Raymond scale score of I (complete obliteration) in 79 aneurysms (56%), II (residual neck) in 40 aneurysms (28%) and III (residual dome) in 21 aneurysms (15%); in one case the Hydrosoft coil could not be placed. Procedural morbidity and mortality were 2.1% and 1.4%, respectively. No complications were definitively attributed to the use of Hydrosoft coils. There were three cases (2.1%) of parent vessel thrombosis, two of which resolved after intraprocedural administration of thrombolytic agents and did not lead to neurological sequelae. The incidences of intraprocedural or periprocedural aneurysmal rupture (2.1%), cerebral hemorrhage (3.5%), stroke (4.9%), vasospasm (26.2%) or hydrocephalus (31.1%) were comparable to contemporary literature.
The use of Hydrosoft coils appears to be safe and does not lead to higher complication rates than are currently accepted in the literature. Further prospective studies are required to determine whether the use of Hydrosoft coils results in a lower incidence of aneurysmal recurrence.
Hydrosoft 线圈的开发目的是作为收尾线圈,以防止颈部的动脉瘤再复发。一些研究表明,随着时间的推移,颈部的内皮细胞愈合,没有复发,因此初始动物研究结果令人鼓舞。然而,存在理论上的担忧,即 Hydrosoft 线圈在颈部扩张时可能会对母血管造成潜在威胁,以及这些线圈是否足够柔韧,能够安全地作为真正的收尾线圈。对来自三个高容量中心的初始 Hydrosoft 线圈临床应用经验进行回顾性分析。
每个中心被要求报告血管造影(动脉瘤位置、动脉瘤最大尺寸、颈部尺寸、术中母血管血栓形成、线圈突出、动脉瘤破裂以及 Raymond 分级和栓塞后闭塞百分比)和临床(破裂状态、Hunt 和 Hess 分级、卒中发生率、出血、血管痉挛和脑积水)数据,数据来源于连续接受 Hydrosoft 线圈放置的患者。
共纳入 141 例患者。栓塞后 Raymond 分级为 I 级(完全闭塞)的动脉瘤有 79 个(56%),II 级(残余颈部)有 40 个(28%),III 级(残余瘤顶)有 21 个(15%);有 1 个病例未能放置 Hydrosoft 线圈。手术发病率和死亡率分别为 2.1%和 1.4%。没有并发症可以明确归因于 Hydrosoft 线圈的使用。有 3 例(2.1%)出现母血管血栓形成,其中 2 例在术中给予溶栓药物后得到解决,没有导致神经后遗症。术中或围手术期动脉瘤破裂(2.1%)、脑出血(3.5%)、卒中(4.9%)、血管痉挛(26.2%)或脑积水(31.1%)的发生率与同期文献报道的相似。
Hydrosoft 线圈的使用似乎是安全的,并且不会导致比目前文献中更高的并发症发生率。需要进一步的前瞻性研究来确定 Hydrosoft 线圈的使用是否会降低动脉瘤复发的发生率。